| Bioactivity | PD 160170 is a compound developed to inhibit low-risk myelodysplastic syndrome-associated anemia with activities that promote red blood cell transfusion independence and increase hemoglobin. |
| CAS | 181468-88-2 |
| Formula | C18H17N3O4S |
| Molar Mass | 371.41 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial |
PD 160170
CAS: 181468-88-2 F: C18H17N3O4S W: 371.41
PD 160170 is a compound developed to inhibit low-risk myelodysplastic syndrome-associated anemia with activities that pr
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.